The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.
Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...
Gold (XAU) hovers near $2,947 as Fed rate cut expectations rise. Silver (XAG) tests key levels amid trade tensions. Can bulls sustain momentum?
Copyright © 2025 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback